Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arpu Shuangxin Oral Liquid is an analgesic and antipyretic medication manufactured by Tianyin Pharmaceutical. The product's active ingredient is benorilate, a chemical codrug formed by the esterification of aspirin (acetylsalicylic acid) and paracetamol (acetaminophen). This unique formulation is designed to provide the combined therapeutic benefits of both drugs while potentially reducing the gastric irritation commonly associated with aspirin. Upon ingestion, benorilate is hydrolyzed into its parent compounds. Aspirin acts as an irreversible inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), thereby blocking prostaglandin synthesis, while paracetamol provides additional pain relief and fever reduction through central nervous system mechanisms. Arpu Shuangxin is primarily used for the treatment of mild to moderate pain, including headaches, joint pain, and neuralgia, as well as for the management of fever. It gained notable recognition for its use in emergency medical supplies during the 2008 Sichuan earthquake relief efforts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Arpu Shuangxin Oral Liquid.